Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the REWIND cardiovascular outcomes study for Trulicity (dulaglutide) with a Biostatistician

Ticker(s): LLY

Who's the expert?

Name: Dr Michael Kattan - PhD

Institution: Cleveland Clinic | Case Western

  • Chairman, Department of Quantitative Health Sciences, at Cleveland Clinic & Professor of Medicine and Professor, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University.
  • Fellow of the American Statistical Association and has held several posts with the Society for Medical Decision Making. 
  • Research is primarily focused on the development, validation, and use of prediction models; has coauthored over 600 articles in peer-reviewed journals. 

Interview Questions
Q1.

Based on the powering of the study, what is the minimum CV risk reduction that would need to be seen for the study to be statistically significant?

Added By: c_admin
Q2.

Can you quantify how the long duration for this study (duration of treatment of ~5.6 years vs. 2.1-3.5 years in the other GLP1 CV outcome studies) impacts the probability of success?

Added By: c_admin
Q3.

Are there any unique features of the statistical analysis method being used in the Rewind study (compared to the Leader and Sustain 6 studies) that would likely impact the probability of success?

Added By: c_admin
Q4.

One analysis that was conducted suggesting the risk reduction would need to be 11% to statistically significant. What are your thoughts on this?

Added By: c_admin
Q5.

If we assume that 50% of the events in the study are coming from patients with established CV disease, and those patients get a 20% CV risk reduction from dulaglutide. And then the remaining 50% of the events come from patients with no previous CV disease, and those patients experience no CV risk reduction from treatment with dulaglutide, does that simply translate into a 10% risk reduction in the overall study? If yes, what is the probability that the study would be successful with an overall 10% risk reduction?

Added By: c_admin
Q6.

 It would be helpful to know how a range of overall risk reduction from 10-20% with dulaglutide would impact the probability of success in the study.

  •  If the overall risk reduction in the study is 10%, what is the probability that the study is statistically significant? (Same for 11-20% overall risk reduction)

Added By: c_admin
Q7.

In the Leader publication,, patients with established CV disease and treated with liraglutide had a 17% reduction in CV risk. Those patients had an average duration of treatment of 3.5 years. What risk reduction would have likely been seen if those patients were treated for 5.5 years?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.